VJOncology is committed to improving our service to you

ESMO 2019 | SCLC hyperprogression with nivolumab

VJOncology is committed to improving our service to you

Martin Reck

Martin Reck, MD, PhD, German Center of Lung Research, Grosshansdorf, Germany, discusses an analysis of tumor hyperprogression (HP) with nivolumab in small- cell lung cancer (SCLC) randomized, placebo-controlled trials. This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter